Validating the risks for the Indian pharmaceutical companies, credit rating agency ICRA said that the US generic business is expected to remain challenging for the Indian companies in 2018. Adding that the Indian pharma companies are expected to record a pricing pressure of 10-12 per cent.
Read more: US generic business to become more challenging for Indian pharmas